Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
German foreign minister backs abandoning EU's unanimity principle - 2This Canadian crater looks like marbled meat | Space photo of the day for Jan. 6, 2026
- 3See a half-lit moon shine among the stars of Aquarius on Nov. 27
- 4Big majority in Germany call Berlin's efforts on gas prices too weak
- 5First Alert: Light snow through this evening
- Thousands of small fish defy gravity to climb Congo waterfall
- South Carolina measles outbreak grows by nearly 100, spreads to North Carolina and Ohio
- Israel has clear objectives south of Litani River, but will face difficult choices further north
- Rick Steves Prefers Paying A Bit Extra For This Delectable Food When Dining In Spain
- Jeff Bezos’ Blue Origin launches landmark Mars mission in New Glenn rocket’s first big test
- Thousands of Walgreens nasal spray bottles recalled. See which ones.
- People who talk with their hands seem more clear and persuasive – new research
- Cheetos and Doritos to launch new versions without artificial dyes
- NASA releases new photos of interstellar comet 3I/ATLAS
